Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies
| dc.contributor.author | Horton, Julie L. | |
| dc.contributor.author | Virag, Jitka | |
| dc.date.accessioned | 2020-04-23T18:33:29Z | |
| dc.date.available | 2020-04-23T18:33:29Z | |
| dc.date.issued | 2019-03-15 | |
| dc.description.abstract | Myocardial tissue damage that occurs during an ischemic event leads to a spiraling deterioration of cardiac muscle structural and functional integrity. Reperfusion is the only known efficacious strategy and is the most commonly used treatment to reduce injury and prevent remodeling. However, timing is critical, and the procedure is not always feasible for a variety of reasons. The complex molecular basis for cardioprotection has been studied for decades but formulation of a viable therapeutic that can significantly attenuate myocardial injury remains elusive. In this review, we address barriers to the development of a fruitful approach that will substantially improve the prognosis of those suffering from this widespread and largely unmitigated disease. Furthermore, we proffer that ephrinA1, a candidate molecule that satisfies many of the important criteria discussed, possesses robust potential to overcome these hurdles and thus offers protection that surpasses the limitations currently observed. | en_US |
| dc.identifier.doi | 10.3390/ijms20061449 | |
| dc.identifier.uri | http://hdl.handle.net/10342/8347 | |
| dc.subject | myocardial infarction; cardioprotection; therapeutic strategies; ephrinA1; ischemia; reperfusion | en_US |
| dc.title | Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies | en_US |
| dc.type | Article | en_US |
| ecu.journal.issue | 6 | en_US |
| ecu.journal.name | International Journal of Molecular Sciences | en_US |
| ecu.journal.pages | 1449 | en_US |
| ecu.journal.volume | 20 | en_US |
Files
Original bundle
1 - 1 of 1